Possis Medical AngioJet
This article was originally published in The Gray Sheet
Executive Summary
Marketing of the LF140 Rheolytic thrombectomy system catheter for use in peripheral arteries begins immediately following 510(k) clearance for the expanded indication, announced April 13. Currently promoted in the U.S. for blood clot removal from coronary arteries, coronary bypass grafts, AV dialysis access grafts and now peripheral arteries, the added indication applies to 100,000 limb-threatened patients in the U.S. annually, representing an added market opportunity of approximately $100 mil